Acute cerebrovascular accident; traumatic brain injury, consequences of traumatic brain injury; encephalopathy; cardiopsychoneurosis; mild cognitive impairment of atherosclerotic origin; anxiety disorders in neurotic and neurosis-like conditions; acute myocardial infarction (from the first day), as part of complex therapy; primary open-angle glaucoma of various stages, as part of complex therapy; relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and autonomic-vascular disorders; acute intoxication with antipsychotic drugs; acute purulent-inflammatory processes in the abdominal cavity (acute necrotic pancreatitis, peritonitis), as part of complex therapy.
active substance: ethylmethylhydroxypyridine succinate;
1 ml of solution contains 50 mg of ethylmethylhydroxypyridine succinate;
excipients: sodium metabisulfite (E 223), water for injection.
Dosage form. Injection.
Basic physical and chemical properties: colorless or slightly yellowish transparent liquid.
Thiamex is an inhibitor of free radical processes, membrane protector, exhibits antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body’s resistance to the effects of various damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication with alcohol and antipsychotics (neuroleptics)).
Thiamex improves cerebral metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. Produces a hypolipidemic effect, reduces total cholesterol and low density lipoprotein (LDL). Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.
The mechanism of action of the drug is due to its antioxidant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, gamma-aminobutyric acid (GABA), acetylcholine), which enhances their ability to bind to ligands-functional organization of neuromembiatic transmission. Thiamex increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in the content of adenosine triphosphate (ATP) and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.
Thiamex normalizes metabolic processes in the ischemic myocardium, reduces the area of necrosis, restores and improves the electrical activity and contractility of the myocardium, and also increases coronary blood flow in the ischemic area, reduces the consequences of reperfusion syndrome in acute coronary insufficiency. Increases the antianginal activity of nitro drugs. Thiamex contributes to the preservation of retinal ganglion cells and optic nerve fibers in progressive neuropathy, the consequences of which are chronic ischemia and hypoxia. Improves the functional activity of the retina and optic nerve, increases visual acuity.
- Acute disorders of cerebral circulation;
- traumatic brain injury, consequences of traumatic brain injury;
- mild cognitive impairment of atherosclerotic genesis;
- anxiety disorders in neurotic and neurosis-like states;
- acute myocardial infarction (from the first day), as part of complex therapy;
- primary open-angle glaucoma of various stages, as part of complex therapy;
- relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
- acute intoxication with antipsychotic drugs;
- acute purulent-inflammatory processes in the abdominal cavity (acute necrotizing pancreatitis,
- peritonitis), as part of complex therapy.
Acute hepatic or renal failure, hypersensitivity to the drug, childhood, pregnancy, lactation.
Interaction with other medicinal products and other types of interactions.
Thiamex enhances the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian drugs (levodopa). Reduces the toxic effect of ethyl alcohol.
Method of administration and dosage
Intramuscularly or intravenously (jet or drip). When administered by infusion, the drug should be diluted in isotonic sodium chloride solution.
Inject Tiamex in a jet slowly over 5-7 minutes, drip – at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.
In acute disorders of cerebral circulation, Tiamex should be used in the first 10-14 days – intravenous drip of 200-500 mg 2-4 times a day, then intramuscularly 200-250 mg 2-3 times a day for 2 weeks.
In case of discirculatory encephalopathy in the phase of decompensation, Thiamex should be administered intravenously by jet or drip in a dose of 200-500 mg 1-2 times a day for 14 days. Then – intramuscularly at 100-250 mg per day for the next 2 weeks.
For the course of prevention of discirculatory encephalopathy, the drug should be administered intramuscularly at a dose of 200-250 mg 2 times a day for 10-14 days.
For mild cognitive impairments in elderly patients and with anxiety disorders, the drug is used intramuscularly in a daily dose of 100-300 mg per day for 14-30 days.
In case of alcohol withdrawal syndrome Thiamex should be administered at a dose of 200-500 mg intravenously or intramuscularly 2-3 times a day for 5-7 days.
In case of acute intoxication with antipsychotic drugs, the drug should be administered intravenously at a dose of 200-500 mg per day for 7-14 days.
In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis), the drug should be prescribed on the first day both in the preoperative and postoperative periods. The doses administered depend on the form and severity of the disease, the prevalence of the process, and the options for the clinical course. Cancellation of the drug should be made gradually only after a stable positive clinical and laboratory effect.
In acute edematous (interstitial) pancreatitis, Thiamex should be prescribed 200-500 mg 3 times a day, intravenously (in isotonic sodium chloride solution) and intramuscularly. Mild severity of necrotizing pancreatitis – 100-200 mg 3 times a day intravenously (in isotonic sodium chloride solution) and intramuscularly. Medium severity – 200 mg 3 times a day, intravenously drip (with isotonic sodium chloride solution). Severe course – at a pulse dosage of 800 mg on the first day, with a double administration regimen; then – 200-500 mg 2 times a day with a gradual decrease in the daily dose. Extremely severe course – at an initial dosage of 800 mg per day until persistent relief of manifestations of pancreatogenic shock, upon stabilization of the state – 300-500 mg 2 times a day intravenously (in isotonic sodium chloride solution) with a gradual decrease in the daily dose.
There have been no strictly controlled clinical studies of the safety of the drug in children, therefore Thiamex should not be used in this category of patients.
In case of overdose, drowsiness is possible. Treatment is detoxification therapy.
Rarely – nausea, dryness of the oral mucosa, allergic reactions, drowsiness, sleep disturbance, anxiety, emotional reactivity, distal hyperhidrosis, headaches, impaired coordination, increased blood pressure, decreased blood pressure.
Store in its original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children.